Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

(RTTNews) - Indaptus Therapeutics, Inc.(INDP), Monday announced the initiation of a new expansion arm in its Phase 1b/2 clinical trial to evaluate the combination of Decoy20 with BeiGene's PD-1 ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

Indaptus Therapeutics announced significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort. Initial clinical data shows promising ...

Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly ...

The INDP-D101 trial will now admit Canadian patients under the existing protocol, which includes weekly dosing of Decoy20. Furthermore, Indaptus intends to propose an amendment to Health Canada to ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics ...

PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body's ability to fight cancer. Combining ...